Breast Cancer Task Force Must Take More Active Role In RFP Development, New Chairman Insists
In Brief: FDA To Review Preclinical Testing, Phase I Protocols At Open Advisory Group Meeting
FDA Pettiness Holds Up Trials with Promising Anticancer Drugs
FDA Proposes Guidelines For Testing New Anticancer Drugs
Breast Cancer Progress Report Summaries
Shubick Committee Support New System for NCU Review, Action On Chemicals
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program









